These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1643199)

  • 21. [Maprotiline in psychiatric ambulatory care].
    Vinar O
    Act Nerv Super (Praha); 1982 May; 24(2):112-8. PubMed ID: 7102223
    [No Abstract]   [Full Text] [Related]  

  • 22. [Further clinical experiences with maprotiline in endogeneous depressions].
    Náhunek K; Svestka J; Rysánek R; Cesková E
    Act Nerv Super (Praha); 1982 May; 24(2):81-7. PubMed ID: 7048835
    [No Abstract]   [Full Text] [Related]  

  • 23. [The Eppendorf Mood and Motivation Scale as assessment procedure in the clinical evaluation of an antidepressive agent].
    Binz U; Wendt G
    Fortschr Med; 1982 Dec; 100(45):2111-7. PubMed ID: 6757074
    [No Abstract]   [Full Text] [Related]  

  • 24. A double-blind study comparing paroxetine and maprotiline in depressed outpatients.
    Szegedi A; Wetzel H; Angersbach D; Dunbar GC; Schwarze H; Philipp M; Benkert O
    Pharmacopsychiatry; 1997 May; 30(3):97-105. PubMed ID: 9211571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined chlorimipramine and maprotiline therapy in therapy-resistant depressions].
    Soucek K
    Act Nerv Super (Praha); 1982 May; 24(2):88-9. PubMed ID: 7102229
    [No Abstract]   [Full Text] [Related]  

  • 26. An open trial of fluvoxamine therapy for panic disorder complicated by depression.
    Spiegel DA; Saeed SA; Bruce TJ
    J Clin Psychiatry; 1996; 57 Suppl 8():37-40; discussion 40-1. PubMed ID: 8698679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Leckman JF; Holzer JC; Barr LC; McCance-Katz E; Heninger GR; Price LH
    Am J Psychiatry; 1993 Apr; 150(4):647-9. PubMed ID: 8465885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Depression in cerebrovascular disorders: a prospective study and the effect of maprotiline therapy].
    Fonck ML; Vergara F
    Rev Med Chil; 1988 Sep; 116(9):887-94. PubMed ID: 3267929
    [No Abstract]   [Full Text] [Related]  

  • 29. Fluvoxamine: a review of the controlled trials in depression.
    Ware MR
    J Clin Psychiatry; 1997; 58 Suppl 5():15-23. PubMed ID: 9184623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antidepressant drugs in anergic schizophrenia. A double-blind cross-over study with maprotiline and placebo.
    Waehrens J; Gerlach J
    Acta Psychiatr Scand; 1980 May; 61(5):438-44. PubMed ID: 6105762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Video rating analysis of effect of maprotiline in patients with dementia and depression.
    Fuchs A; Hehnke U; Erhart C; Schell C; Pramshohler B; Danninger B; Schautzer F
    Pharmacopsychiatry; 1993 Mar; 26(2):37-41. PubMed ID: 8378411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of major affective disorder with fluvoxamine.
    Lapierre YD; Browne M; Horn E; Oyewumi LK; Sarantidis D; Roberts N; Badoe K; Tessier P
    J Clin Psychiatry; 1987 Feb; 48(2):65-8. PubMed ID: 3100510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maprotiline (Ludiomil)--another antidepressant.
    Med Lett Drugs Ther; 1981 Jun; 23(13):58-9. PubMed ID: 7017367
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine.
    Nolen WA; van de Putte JJ; Dijken WA; Kamp JS; Blansjaar BA; Kramer HJ; Haffmans J
    Acta Psychiatr Scand; 1988 Dec; 78(6):668-75. PubMed ID: 3146890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brofaromine vs. maprotiline plus lithium in treatment-resistant depressed outpatients.
    Hoencamp E; Haffmans PM
    Psychiatry Res; 1991 Mar; 36(3):333-5. PubMed ID: 2062972
    [No Abstract]   [Full Text] [Related]  

  • 36. Prophylactic efficacy of maprotiline on unipolar depression relapse.
    Rouillon F; Serrurier D; Miller HD; Gerard MJ
    J Clin Psychiatry; 1991 Oct; 52(10):423-31. PubMed ID: 1938979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Placebo-controlled trial of mianserin and maprotiline in primary depressive illness: a preliminary report.
    Edwards JG; Goldie A
    Br J Clin Pharmacol; 1983; 15 Suppl 2(Suppl 2):239S-248S. PubMed ID: 6337611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Psychometric findings in treatment using the selective MAO-A inhibitors moclobemide and maprotiline].
    Classen W
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():41-3. PubMed ID: 2587675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives.
    Emrich HM; Berger M; Riemann D; von Zerssen D
    Pharmacopsychiatry; 1987 Mar; 20(2):60-3. PubMed ID: 3108909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind, multicentre study of paroxetine and maprotiline in major depression.
    Schnyder U; Koller-Leiser A
    Can J Psychiatry; 1996 May; 41(4):239-44. PubMed ID: 8726790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.